Oak Park, IL, United States of America

Robert Moriarty

USPTO Granted Patents = 3 


Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 59(Granted Patents)


Company Filing History:


Years Active: 1997-1998

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Robert Moriarty

Introduction

Robert Moriarty is an accomplished inventor based in Oak Park, Illinois. He has made significant contributions to the field of pharmaceuticals, particularly in methods for treating infections and inhibiting angiogenesis. With a total of three patents to his name, Moriarty's work reflects a commitment to advancing medical science.

Latest Patents

Moriarty's latest patents include a method for treating infection using steroid-based pharmaceuticals. Another notable patent focuses on inhibiting angiogenesis using squalamine. This method involves administering an effective amount of squalamine or a pharmaceutically acceptable salt of squalamine to a patient. The detailed chemical formulations and methodologies outlined in his patents demonstrate his innovative approach to addressing complex medical challenges.

Career Highlights

Moriarty is currently associated with Magainin Pharmaceuticals, Inc., where he continues to develop groundbreaking pharmaceutical solutions. His work has garnered attention for its potential impact on treating various medical conditions.

Collaborations

Moriarty collaborates with notable colleagues, including Leah L. Frye and Michael A. Zasloff. These partnerships enhance the research and development efforts at Magainin Pharmaceuticals, fostering an environment of innovation.

Conclusion

Robert Moriarty's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…